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Study of Some Biological Indices of the
State of the Sympathoadrenaline System
under the Effect of Polychiorocamphene
by U. A. Kuz'minskaya* and V. A. Ivanitskii*
The effect of exposure to different amounts of polychlorocamphene (toxaphene) on the level of
catecholamines (noradrenalin and adrenalin), their precursors (DOPA and dophamine), and a metabolite
(vanillylmandelic acid) in tissues (adrenals, brain, heart) and daily urine in white male rats has been
studied.
It was established that the single administration of 120 mg/kg toxaphene (half the LD50) as well as 2.4
mg/kg daily (1/100 of LI50) for 1 and 3 months produced a disturbance of catecholamine metabolism.
The absolute level of ratio of separate components of the sympathicoadrenalic system is unequally
changed in tissues, the breakdown ofcatecholamines is increased, and the specificity oftheir excretion is
destroyed.
The widespread use of organochlorine pesticides
in agriculture in the USSR makes it necessary to
determine the nature ofthe response reactions ofan
organism to these substances.
The sympatho-adrenaline system, one ofthe most
important of the regulating systems ofan organism,
plays an important role in the response reaction of
an organism to the effect of harmful factors.
The basic components of the system are
pyrocatecholamines or catecholamines, compounds
incorporating in their structure the nature of the
primary stimulants of protoplasm, and amines and
oxidation-reduction systems, quinonepyrocatechols
(1).
Hormones produced in the chromaffinic cells of
the suprarenal glands, the paraganglia of the sym-
pathetic nerve nodes, sympathetic nerve endings
and other accumulations ofchromaffinic tissues are
referred to as catecholamines. The biosynthesis and
decomposition of catecholamines is quite well
known (-6).
The initial product for the biosynthesis of
catecholamines is the amino acid tyrosine, which,
under the effect of the highly specific enzyme
tyrosinehydroxylase, is changed into dihydroxy-
phenylalanine (DOPA). During the participation
of dopadecarboxylase, DOPA decarboxylates,
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forming dopamine. The latter hydroxylyzes and
forms noradrenaline, which is transferred to adren-
aline as the result of methylation.
The decomposition of catecholamines basically
occurs by means of O-methylation under the effect
of catechol-O-methyltransferase and subsequent
deamination in the presence of monoaminoxydase.
Vanillylmandelic acid is formed under these condi-
tions which is common both for adrenaline and
noradrenaline as the terminal product of metab-
olism. In addition to this, adrenaline may be sub-
jected to oxidation with the subsequent formation of
quinoid and indole type structures: adrenochrome,
adrenolutin, and 5,6-dioxy-N-methylindole.
Catecholamines, their precursors and metabo-
lites, being biologically active substances, take part
in regulating physiological processes and adaptive
reactions. Because of this, changes in the
catecholamine content in tissue can be one cause of
the disturbance of these processes.
The aim of the present work is the study of the
functional state of the sympatho-adrenaline system
under conditions of administering polychlorocam-
phene (toxaphene) to white rats. Polychlorocam-
phene is an organochlorine pesticide which is
widely used both in the United States and the Soviet
Union.
The following serve as the indices of the state of
the sympatho-adrenaline system: the content in the
adrenal gland, cerebrum and the myocardium of
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their precursors (DOPA and dopamine) and also the
amount ofcatecholamines excreted with urine, pre-
cursors of the catecholamines and the metabolite
(vanillylmandelic acid).
The polychlorocamphene was administered or-
ally to the experimental animals either in single
doses of 120 mg/kg (half the LD0,,) or as 2.4 mg/kg
(0.01 LD0,,) daily for I and 3 months. In the single
dose, the studies were conducted 1, 5, and 15 days
after the introduction of the substance.
Amounts of adrenaline, noradrenaline, DOPA,
and dopamine were determined fluorometrically in
tissues by the method of Matlina and Rakhamanova
(7). The method of Matlina et al. (8) was used for the
analysis of urine. The vanillylmandelic acid content
was determined by the paper chromatography
method (9). Data on the catechol metabolite content
in the tissues and urine of the control animals are
given in Table 1.
Our studies show that a single large dose of
polychlorocamphene (120 mg/kg) results in de-
creasing the amount of adrenaline in the adrenal
glands to 955 ± 100,g/g, i.e., by 24% with respect
to the control group and an increase in the adren-
aline (by 122%) and noradrenaline (by 94%) in the
daily urine during the first 24 hr. No changes were
observed in the cerebrum. In the myocardium a
verifiable reduction was observed in the DOPA
level (down to 0.362 + 0.082,g/g, i.e., a reduction
of 40%) (Table 2).
After 5 days, the level of adrenaline increases in
the adrenal glands up to 1879 + 186,g/g (by 50%)
and the amount of noradrenaline falls in all of the
studied tissues: adrenal glands, cerebrum, and the
myocardium (by 50% on the average). Under these
conditions, the amount ofdopamine in the myocar-
dium increases by 97% and constitutes 6.848 ±
1.163 ,ug/g.
After 15 days, the adrenaline in the adrenal glands
increases to 2111 + 109Ag/g (by 68%), in the cere-
brum the adrenaline increases to 0.094 ± 0.024,ug/g
(by 235%), the noradrenaline increases to 0.391 +
0.017 ,ug/g (by 66%) and dopamine increases to
4.200 ± 0.593,ug/g (by 56%). In the myocardium the
dopamine increases to 7.458 ± 1.377,g/g (by 115%)
Table 1. Catecholamines, their precursors and metabolites in the tissues and urines of control animals.
Catecholamines
Index studied Adrenal gland, ,ug/g Brain, ,glg Heart, ,g/g Urine, ,ug/day
DOPA 109 ± 7 0.183 ± 0.035 0.608 ± 0.064 0.556 ± 0.079
Dopamine 126 ± 27 2.692 ± 0.307 3.462 ± 0.563 3.597 ± 0.641
Noradrenaline 558 + 62 0.236 ± 0.028 0.968 ± 0.174 0.627 ± 0.107
Adrenaline 1250 ± 72 0.028 ± 0.004 0.138 ± 0.018 0.225 ± 0.033
Vanillylmandelic acid 22.4 ± 1.5
Tabel 2. Changes in the level of catecholamines, their precursors and metabolites, in the tissues and urine after a single dose of
polychlorocamphene.
Time
after dose of Change in catecholamine level, %11
polychlorocamphene,
Index days Adrenals Brain Heart Urine
DOPA 1 -40
Dopamine I
Noradrenaline 1 94
Adrenaline 1 -24 122
Vanillylmandelic acid I - - -
Dopa 5
Dopamine 5 97
Noradrenaline 5 -48 -50 -58
Adrenaline 5 50
Vanillylmandelic acid
DOPA 15 -46
Dopamine 15 56 115
Noradrenaline 15 66
Adrenaline 15 68 235
Vanillylmandelic acid 15
11 Values given are percent with respect to control group. A positive value indicates an increase with respect to controls; a negative
value indicates a decrease. Only significant (p < 0.05) changes are given.
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0.334 + 0.092 ,g/g (a decrease of46%). The excre-
tion with urine, the same as after 5 days, remains
within normal limits.
As a result, a large single dose of a large
polychlorocamphene stresses the sympatho-
adrenaline system which during the first 24 hr re-
sults in an increased release ofcatecholamines with
urine and in a reduction of the adrenaline level in
the adrenal glands. The manifested changes can be
considered either as the result of an intensified dis-
charge of catecholamines or as the result of the
disturbance of the synthesis of catecholamines in
the adrenal glands and of the catabolism in the tis-
sues. The increase in the amount of adrenaline
noted after 5 days in the adrenal glands is obviously
compensatory in nature and is conditioned by the
activation of noradrenaline methylation which re-
sults in the observed reduction in its level in all
tissues.
The data obtained on day 15 after the single
dose administration of polychlorocamphene are of
interest. These data attest to the accumulation of
dopamine in the myocardium and the intensification
of the biosynthesis of catecholamines in the cere-
brum. This results in a sharp increase of the
catecholamine level, particularly of adrenaline. Be-
cause of this, the ratio of adrenaline to norad-
renaline is more than doubled. Such a late reaction
of cerebral tissue can obviously be related to par-
ticulars associated with the permeation of
polychlorocamphene into the central nervous sys-
tem. In our earlier experiments (10), it was shown
that the single-dose administration of polychloro-
camphene to rats in a dose of 120 mg/kg (0.5 LD50)
results in observing the pesticide in the lipids ofthe
brain 15 days after introduction.
Consequently, the organism reacts with a stress
reaction to a single large dose oftoxin. This type of
stress reaction is characterized by an intensified
release of adrenaline and the reaction is directed
towards maintaining homeostasis. Nevertheless,
the process does not terminate with this. Later on
disturbances arise in catecholamine metabolism in
such vital organs as the brain and heart. These dis-
turbances serve as the reason for the clinically ob-
served damage to the nervous system and the
myocardium (11-14) for polychlorocamphene expo-
sure. Long-term introduction of 2.4 mg/kg (0.1
LD,,,) polychlorocamphene evokes significant
changes in the functional activity of the sympatho-
adrenaline system (Table 3). After I and 3 months of
the daily exposure to the substance, the adrenaline
level in the urine rises to 0.321 + 0.030 ,ug/day (by
42%) after a month and twice the initial level after 3
months, constituting 0.450 ± 0.050 ,ug/day. An av-
erage increase of44% was observed in the metabo-
lite ofcatecholamines-vanillylmandelic acid (32.6 ±
5.5,ug/day after 1 month and 31.9 ± 6.9,g/day after
3 months). After I month, the amount of DOPA
released falls to 0.317 ± 0.036 gg/day (a reduction
of43%) and after 3 months the amount ofdopamine
increases to 5.668 ± 0.641 ,ug/day (an increase of
57%). The persistent increase in the amount of van-
illylmandelic acid in the urine provides a basis for
considering that the long-term administration of
polychlorocamphene results in the intensification of
catecholamine break-down.
The amount of adrenaline doubles in the brain
(0.056 ± 0.007 pig/g after 1 month and 0.051 ± 0.004
,ug/g after 3 months). As a result, the ratio between
the catecholamines (adrenalin/noradrenaline) in-
creases by a factor of three after I month and by a
factor of two after 3 months.
Significant changes are detected in the myocar-
dium. Long-term administration of polychlorocam-
Table 3. Changes in the level ofcatecholamines, their precursors and metabolites in tissues and urine during long-term administration of
0.01 LD50 (2.4 mg/kg) polychlorocamphene.
Time
after initial dose Change in catecholamine level, %"
Index months Adrenals Brain Heart Urine
DOPA 1 -32 -43
Dopamine 1 78
Noradrenaline 1 -41
Adrenaline 1 100 -38 42
Vanillylmandelic acid 1 45
DOPA 3 -45
Dopamine 3 73 56 57
Noradrenaline 3 -46
Adrenaline 3 51 82 100
Vanillylmandelic acid 3 42
a Values given are percent with respect to control group. A positive value indicates an increase with respect to controls; a negative
value indicates a decrease. Only significant (p < 0.050) changes are given.
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DOPA-decarboxylase which results in reducing
DOPA to 0.418 + 0.057,g/g (by 32%) after 1 month
and to 0.338 + 0.074 ,ug/g (by 45%) after 3 months,
and in increasing dopamine to 6.083 + 1.074 gg/g
(by 78%) after 1 month and 5.304 ± 0.740 ,ug/g (by
56%) after 3 months, i.e., the same as was observed
15 days after the single-dose administration of the
substance. Nevertheless, in the case of multiple in-
troductions of the substance, an augmenting factor
appears to be the observed reduction in the amount
of noradrenaline (0.571 ± 0.067 ,ug/g after 1 month
and 0.529 ± 0.096 ,ug/g after 3 months, a reduction
of 45% on the average) and a reduction of adren-
aline of38% (0.086 ± 0.11 and 0.098 ± 0.015,Lg/g).
The latter may be considered from one point ofview
as the result of the inhibition of catecholamine
biosynthesis at the dopamine-f8-hydroxylase level,
from another point of view, it may be considered
the result of the reduced capacity of the myocar-
dium for absorbing the catecholamines from blood.
As the results of the shifts which took place in the
myocardium, the ratio of the amount of
catecholamines and their precursors was reduced
three times: (A +NA)/(D+ DN) is 0.27 for the con-
trol group; after 1 and 3 months of polychlorocam-
phene introduction, this ratio was -0.10.
The obtained data attest to the high sensitivity of
myocardium to the entrance of polychlorocam-
phene. This is in agreement with the clinically ob-
served results and with studies of the isoenzyme
spectra of lactate dehydrogenase (LHD) of blood
serum, where the most characteristic changes were
changes in the LHD-LDH1 and LDH2 heart frac-
tions (15). It can be assumed that tachycardia, an-
gina pains, and changes in the EKG which take
place during exposure to polychlorocamphene and
are characteristics for diffusion hypoxy of the car-
dium (16) are conditioned by the significant ac-
cumulation of polychlorocamphene in the myocar-
dium (17) and are related to the development of an
imbalance of catecholamines. On the one hand, an
increase of the dopamine level in the myocardium
increases the heart rate and changes the rhythm
(18); on the other hand, a reduction in the amount of
catecholamines (adrenaline and noradrenaline) re-
duces the activity of the metabolic processes, en-
suring the necessary energy potential (19).
Damage to the nervous system which is charac-
teristic for exposure to polychlorocamphene can be
related to the build-up of catecholamines in brain
tissue, since it is known that an excess ofadrenaline
reduces the excitability of the hypothalamic region
and the sympatheric adjoining trunk (19). According
to previous data (12-14), the following were ob-
served in the case of polychlorocamphene expo-
sure: headaches, paresthesia, insomnia, sleep dis-
orders of the narcolepsy type, anisocoria, nyosis,
intermittent disturbances in the blood circulation of
the brain, and other sign of vegetative-vascular
disturbances, indicating a functional inadequacy of
the hypothalamus trunk of the brain.
We can conclude on the basis ofthe obtained data
that the ingestion of polychlorocamphene distorts
catecholamine metabolism. Atypical changes take
place in tissue of the absolute amount and ratio
between the individual components of the
sympatho-adrenaline system, the nature of their
release is disturbed, and catecholamine breakdown
is intensified in the case of the long-term introduc-
tion of the substance. All of the above may be the
reason for the manifestation of inadequate reac-
tions, disturbed metabolism, and inadequate func-
tion of vital organs and systems.
It should be noted that the nature ofthe excretion
ofthe components of the sympatho-adrenaline sys-
tem with urine is not always correlated with the
state of catecholamine metabolism in tissue, par-
ticularly in the case of the single large dose of
polychlorocamphene. We must study not only the
nature of the excretion of catecholamines with
urine, but also their metabolism in tissues in order
to uncover the pathogenesis ofthe untoward effects
of chemical factors.
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